# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (date of earliest event reported): April 8, 2005

## PEDIATRIX MEDICAL GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)

		Florida	001-12111	65-0271219
- (S	tat	e or Other Jurisdiction of Incorporation)		(IRS Employer
			. Concord Terrace .se, Florida 33323	
-		(Address of p	orincipal executive off	ice)
Re	gis	trant's telephone number, inc	cluding area code (954)	384-0175
si	mul:	the appropriate box below if taneously satisfy the filing wing provisions:		
[	]	Written communications pursu (17 CFR 230.425)	ant to Rule 425 under t	the Securities Act
]	]	Soliciting material pursuant (17 CFR 240.14a-12)	to Rule 14a-12 under 1	the Exchange Act
]	]	Pre-commencement communicati Exchange Act (17 CFR 240.14d		4d-2(b) under the
]	]	Pre-commencement communicati Exchange Act (17 CFR 240.13e		Be-4(c) under the

Item 2.02 Results of Operations and Financial Condition.

On April 8, 2005, Pediatrix Medical Group, Inc. (the "Company") issued a press release (the "Press Release") announcing that its results of operations for the three months ended March 31, 2005 would include a pre-tax charge of \$6 million resulting from a settlement offer made by the Company on April 7, 2005 in connection with its previously announced national Medicaid and TRICARE investigation. A copy of the Press Release is attached hereto as Exhibit 99.1. The information set forth in this Item 2.02 shall be considered to be filed with the Securities and Exchange Commission.

### Item 7.01 Regulation FD Disclosure.

In the Press Release, the Company reaffirmed its expectation that its earnings per share for 2005 would be in the range of its previously issued guidance, less the after-tax impact of the charge announced in the Press Release and any future charge related to the national Medicaid and TRICARE investigation. The Company will not update or revise its 2005 earnings guidance for any future adjustment to its reserves relating to the investigation. The Company will report future adjustments, if any, in a press release covering its results of operations for

the period to which the adjustment relates.

The information set forth in Item 7.01 of this Current Report, and the exhibit to this Current Report, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 7.01 of this Current Report and in such exhibit shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Item 9.01(a) Financial Statements of businesses acquired:

Not applicable.

Item 9.01(b) Pro Forma Financial Information:

Not applicable.

Item 9.01(c) Exhibits:

99.1 Press Release of Pediatrix Medical Group, Inc. dated April 8, 2005.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PEDIATRIX MEDICAL GROUP, INC.

Date: April 8, 2005 By: /s/ Karl B. Wagner -----

Name: Karl B. Wagner Title: Chief Financial Officer

## Exhibit Index

- ------

99.1 Press Release of Pediatrix Medical Group, Inc. dated April 8, 2005.

Pediatrix Announces \$6 Million Pre-Tax Charge for National Medicaid Investigation

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 8, 2005--Pediatrix Medical Group, Inc. (NYSE:PDX), the nation's largest provider of newborn and maternal-fetal physician services today announced that its results for the three months ended March 31, 2005 would include a pre-tax charge of \$6 million resulting from an increase in reserves for liabilities that represent the Company's estimate of the minimum probable losses in connection with its previously announced pending national Medicaid and TRICARE investigation. The Company increased its reserves based on a settlement offer that it made to representatives of the government yesterday.

The Company reaffirmed its expectation that its earnings for 2005 would be in the range of its previously issued guidance, less the after tax impact of this charge and any future charge related to this matter.

As settlement discussions continue, the Company may record additional adjustments to its reserves. The Company will not update or revise its 2005 earnings guidance for any future adjustment to its reserves relating to the national Medicaid and TRICARE investigation. The Company will report future adjustments, if any, in its earnings release covering the period to which the adjustment relates.

There can be no assurance that the Company's existing offer or any future offer will result in a settlement of the investigation or that eventual losses related to this matter will not materially exceed the Company's current reserves.

#### About Pediatrix

Pediatrix was founded in 1979. Pediatrix physicians and advanced nurse practitioners are reshaping the delivery of maternal-fetal and newborn care, identifying best demonstrated processes and participating in clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Its neonatal physicians provide services at more than 220 NICUs, and through Obstetrix, its perinatal physicians provide services in many markets where Pediatrix's neonatal physicians practice. Combined, Pediatrix and its affiliated professional corporations employ more than 775 physicians in 31 states and Puerto Rico. Pediatrix is also the nation's largest provider of newborn hearing screens and newborn metabolic screening. Additional information is available at http://www.pediatrix.com.

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe", "hope", "may", "anticipate", "should", "intend", "plan", "will", "expect", "estimate", "project", "positioned", "strategy" and similar expressions, and are based on assumptions and assessments made by Pediatrix's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in Pediatrix's most recent Annual Report on Form 10-K, including the section entitled "Risk Factors".

CONTACT: Pediatrix Medical Group, Inc., Fort Lauderdale Bob Kneeley, 954-384-0175, x-5300 bob\_kneeley@pediatrix.com